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OBJECTIVES: The probability of contracting a hospital acquired infection increases
the longer an individual is hospitalised. The purpose of this analysis is to quantify
the additional probability of contracting Clostridium Difficile Infection (CDI) for each
additional day spent in the hospital.METHODS:Using the English Hospital Episode
Statistics (HES) database, the number of inpatient days before diagnosis of hospi-
tal-acquired CDI and the total number of inpatient days for patients that do not
acquire CDI are calculated. This time-to-event variable, along with a set of covari-
ates, is used in a binary logistic regression to predict the added probability of
contracting CDI for each additional day in the hospital. Patients in this analysis
were over 50 years old, had a length of stay (LoS) less than 50 days, and had a
co-morbidity of chronic obstructive pulmonary disease (COPD), heart failure, dia-
betes, or kidney disease. RESULTS: The average LoS for all patients, patients with
CDI, and patients without CDI, was 5.48 days (28.46), 26.24 days (212.86), and
5.38 days (28.46), respectively. The average LoS before acquiring CDI was 6.27
days (212.81). For each additional day spent in the hospital, a patient has 4.40%
greater chance of contracting the disease (OR1.044; s.e.0.001; p0.01). Increased
age (OR1.134; s.e.0.019; P0.01) and being female (OR1.28; s.e.0.034; p0.01)
were also predictors of CDI diagnosis. CONCLUSIONS: This model quantifies the
increased likelihood of hospital acquired infections associated with longer dura-
tion inpatient admissions. Such infections are associated with much more severe
health outcomes and are a significant burden on hospital resources.
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OBJECTIVES: Following solid organ transplantation (SOT) or hematopoietic stem
cell transplantation (HSCT), patients are at risk of cytomegalovirus (CMV) disease.
The impact of CMV disease on mortality and hospitalisation costs following trans-
plantation and on the probability of transplant rejection following SOT was
estimated. METHODS: We conducted a retrospective cohort study of a database of
hospitalisations in France (PMSI). Available data included demographics, hospital
characteristics, diagnoses, health care procedures, length of stay, discharge status
and costs. Logistic regression was used to estimate the impact of CMV disease
during initial hospitalisation on the probability of graft rejection and mortality
during initial stay or following readmission. The impact of CMV disease on costs
was estimated using generalised linear modelling. All estimates were adjusted on
age, gender and transplant type. A first analysis based on hospitalisation records
from 2007 was performed; additional analyses accounting for patient censoring,
with the data from 2008 to 2011, are planned. RESULTS: Among 4,078 SOT recipi-
ents and 3,530 HSCT recipients, CMV disease was reported during initial stay in 65
(1.59%) and 67 (1.90%) patients respectively. Case fatality rates were 5.37% and
3.23% in the SOT and HSCT recipients. CMV disease was associated with an in-
creased mortality following HSCT (odds ratio  3.614, p0.0018), but not following
SOT (OR1.087, p0.83). Graft rejection was recorded for 11.53% of SOT recipients
and the odds ratio of rejection associated with CMV was 2.71 (p0.0007). Average
hospitalisation costs were €45,700 for HSCT and €32,200 for SOT. CMV disease was
associated with increases in costs by 90.37% (p0.0001) for HSCT and 86.14%
(p0.0001) for SOT. CONCLUSIONS: CMV disease is associated with substantial
increases in probability of graft rejection, mortality and hospitalisation costs in
French transplant recipients. The costs and serious adverse events of antiviral
therapy for CMV prophylaxis or pre-emption add to this burden.
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OBJECTIVES: No cure for HIV currently exists, however antiretroviral (ARV) drugs
can control disease progression. The objective of this study was to carry out a
mixed-treatment comparison (MTC) of randomized controlled trials (RCTs) to as-
sess the relative efficacy and safety of ARV drugs used in treatment-experienced
(TE) patients. MTCs synthesise available evidence by combining direct and indirect
comparisons. METHODS: All phase II and III RCTs published in the past five years,
assessing the efficacy of etravirine (ETR), maraviroc (MVC) and raltegravir (RAL) in
combination with optimized background therapy (OBT) compared to OBT alone in
TE HIV patients were identified. Data on patient characteristics, CD4 cell count
changes, virological suppression (percentage of HIV RNA 50 copies/mL and 400
copies), common adverse events (diarrhoea, nausea), discontinuations and deaths
were extracted. A Bayesian fixed-effect mixed-treatment network analysis was
performed on efficacy and safety outcomes at 48 and 96 weeks. RESULTS: Twenty-
two studies were identified; six were included in the MTC network based on data
availability (i.e. BENCHMRK 1 and 2, DUET 1 and 2 and MOTIVATE 1 and 2). All
treatments showed increased efficacy compared to OBT. MVC twice daily was as-
sociated with an increased virological suppression (mean odds ratio 1.66 for400
copies and 1.88 for  50 copies) and larger CD4 count increase (mean change of 40
cells/mL) compared to ETR at 48 weeks. MVC’s superior efficacy to ETR was main-
tained at week 96. MVC was no different to RAL at week 48 but superior to RAL at 96
weeks for both efficacy outcomes. For safety outcomes, no differences between
treatments were found.CONCLUSIONS: In the absence of head-to-head trials com-
paring active drugs, this study provides information on the relative efficacy of each
regimen. It confirms the significant clinical value of MVC compared to ETR and RAL
in treatment-experienced patients.
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OBJECTIVES: Ceftaroline fosamil, the prodrug of the active metabolite ceftaroline,
is a broad-spectrum intravenous cephalosporin with bactericidal activity against
common pathogens causing CAP. The objective was to evaluate the efficacy of
ceftaroline fosamil compared with other antibiotics recommended for initial em-
piric treatment of adults admitted to hospital with moderately severe CAP.
METHODS: MEDLINE, Medline-In-Process, EMBASE and the Cochrane Controlled
Trials Registry were searched to identify published trials in which ceftaroline fos-
amil, ampicillin/sulbactam, ceftriaxone (1g or 2g q24h), cefuroxime, cefotaxime,
co-amoxiclav, ertapenem, levofloxacin and moxifloxacin were used to treat hospi-
talised patients with CAP. Primary outcomes were clinical success at test-of-cure
visit in the modified intention-to-treat (MITT) and clinically evaluable (CE) popula-
tions using a NMA with uninformative priors. Clinical success for each antibiotic
was reported with 95% credible intervals (CrI95%). A fixed effects model was used.
RESULTS: Twelve studies (24 treatment arms) with a total of 4,647 patients with
CAP were included in the analysis. Five studies involving 2,888 patients were in-
cluded in the MITT analysis and 9 studies with 3,182 patients in the CE analysis.
The pooled clinical success rates (CrI95%) in the MITT population for each antibi-
otic were: ceftaroline fosamil 75.5% (71.3% to 79.4%), ceftriaxone 68.2% (65.6% to
70.6%), levofloxacin 74.3% (67.3% to 80.4%), and moxifloxacin 73.8% (67.1% to
79.7%). Clinical success rates (CrI95%) in the CE population were ceftaroline fosamil
85.9% (81.4% to 89.6%), ceftriaxone 79.7% (77.3% to 82.0%), co-amoxiclav 64.6%
(46.9% to 78.4%), ertapenem 79.8% (70.3% to 87.0%), levofloxacin 85.5% (77.2% to
91.2%), and moxifloxacin 81.7% (75.2% to 86.9%). CONCLUSIONS: The results sug-
gest that ceftaroline fosamil may be at least as effective as other antibiotics used in
the initial empiric treatment of adults admitted to hospital with CAP. This analysis
is limited by the small number of studies that were found, making controlling for
heterogeneity challenging.
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OBJECTIVES: Chronic Hepatitis C virus (HCV) infection is one of the silent global
epidemics with significant unmet need and disease burden. One of the major lim-
itations of current treatments is the need for 12 or 6 months of Interferon based
therapy, which has tolerability and toxicity issues for many patients. During last
2-3 years several new agents have been tested in clinic, which have shown prom-
ising results as non-interferon based therapy. Goal of this study was to review the
clinical efficacy and safety profile of non-interferon based therapies for HCV
treatment. METHODS: We searched the MEDLINE, and abstracts from AASLD and
EASL until May 2012. Studies were selected for clinical trials on direct acting agents
for HCV. Primary endpoints reviewed were Sustained Viral Response (SVR). Toxic-
ity was evaluated as secondary endpoint. Aggregated data were further analyzed to
understand comparative safety and efficacy. RESULTS: Until May 2012, results of
five eligible HCV clinical trials for interferon free regimens were available. Overall,
treatment with combination of protease and polymerase inhibitor showed dra-
matic viral load reduction after 2 weeks of treatment. The combination of PSI-7977
and PSI-938 showed 93% viral clearance after 14 days (n16). The combination of
RG7227 and RG7128 demonstrated 5.1 log reduction in viral load in treatment naive,
and 4.9 log reduction in null responder patients after 14 days of treatment. The
combination of BMS-790052 and BMS 650032 showed 36.3% 24 week SVR in null
responder patients. One study evaluating VX-222 and Telaprevir combination was
discontinued due to viral breakthrough. Several studies are currently on-going
whose data would be available in 2012-2013. CONCLUSIONS:Non-interferon based
therapies have shown impressive viral load reduction in short term studies. How-
ever, more data for SVR, viral breakthrough and resistance is needed to confirm
their safe use in HCV infected population.
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OBJECTIVES: Ceftaroline fosamil, the prodrug of the active metabolite ceftaroline,
is a novel intravenous cephalosporin with in vitro bactericidal activity against
resistant Gram-positive pathogens, including methicillin-resistant Staphylococcus
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aureus(MRSA), streptococci and many common Gram-negative pathogens. The ob-
jective was to evaluate the efficacy of ceftaroline fosamil monotherapy versus
other antibiotics routinely used in initial empiric treatment of MRSA-suspected
CSSTI. METHODS: MEDLINE, Medline-In-Progress, EMBASE and the Cochrane Con-
trolled Trials Registry were searched to identify published randomised controlled
trials in which ceftaroline fosamil, daptomycin, linezolid, teicoplanin, tigecycline
and vancomycin (with or without a Gram-negative antibiotic) were used to treat
patients admitted to hospital with CSSTI. Primary outcomes were clinical success
at test-of-cure visit in the modified intention-to-treat (MITT) and clinically evalu-
able (CE) populations using a NMA with uninformative priors. Clinical success for
each antibiotic was reported with 95% credible intervals (CrI95%). A fixed effects
model was used. RESULTS: Thirteen studies involving five antibiotics and a total of
8,152 patients with CSSTI were included. No data were found for teicoplanin.
Pooled clinical success rates and CrI95% in the MITT population for each antibiotic
were: ceftaroline fosamil 81.2% (CrI95%: 76.8% to 85.0%), daptomycin 81.4% (CrI95%:
72.5% to 87.9%), linezolid 84.9% (CrI95%: 80.0% to 88.8%), tigecycline 79.9% (CrI95%:
74.1% to 84.7%) and vancomycin 80.4% (CrI95%: 77.9% to 82.6%). Clinical success
rates in the CE population were: ceftaroline fosamil 89.2% (CrI95%: 85.3% to 92.3%),
daptomycin 93.3% (CrI95%: 88.5% to 96.2%), linezolid 94.2% (CrI95%: 90.7% to 96.5%),
tigecycline 88.1% (CrI95%: 84.7% to 90.9%) and vancomycin 90.0% (CrI95%: 88.2% to
91.6%). CONCLUSIONS: Although limited data were identified and differences
across trials were noted, the results of this NMA suggest that ceftaroline fosamil is
comparable in efficacy to other antibiotics used in the treatment of MRSA-sus-
pected CSSTI.
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OBJECTIVES: Quadrivalent human papillomavirus (qHPV) vaccine prevents from
genital warts in addition to HPV-related cancers. Study objective was to provide
first estimates of savings offered by the reduction in GW incidence observed in
Belgium, 4 years after the introduction of the qHPV vaccine. METHODS: A retro-
spective observational study was performed using the MLOZ health care insurance
database. Number of GW was described by age-group, gender, between 2003 and
March 2011. GW cumulative incidence estimates were compared between women
vaccinated or not with qHPV vaccine from 2007 onwards. Analyses were restricted
to age-groups of women likely to have been vaccinated. Direct medical treatment
costs published were updated to €2010 using the purchasing parity power conver-
sion rates method and estimated at 324.2€/case (public health care payer
perspective).RESULTS:A total of 55,193 women aged 16-20 year-old were retrieved,
of whom 13,117 were vaccinated with qHPV vaccine. Within this age-group, 435
first GW cases were observed, 423 in the control group (non vaccinated: 1.01%) and
12 in the vaccinated group (0.09%), representing 920 GW cases/100,000 vaccinated
women avoided among this age group during a limited period of 4 years. Cumula-
tive incidence estimates of GW were also significantly lower among women vacci-
nated with qHPV vaccine compared to those that were not: 0.12% (CI: 0.07%-0.23%)
vs. 0.93% (CI: 0.85%-1.03%), relative reduction (RR): -87.1%, p0.0001. Among girls
aged 16-20 and over 4 years, direct health care cost saved were estimated at 298K€/
100,000 vaccinated girls. CONCLUSIONS: This preliminary analysis suggests that a
marked reduction of GW and related resources used in Belgium may be achievable
through qHPV vaccination. The reduction of GW and associated treatments costs
would be higher if more cohorts were considered and should become more prom-
inent in the coming years when the current and future qHPV vaccinated cohorts
will enter into the peak age of risk for GW.
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OBJECTIVES: We studied the influence of absolute and relative contraindications
on likelihood of treatment with dual-therapy for chronic heptatis C (HCV) infection
in a national cohort of HCV-infected veterans. METHODS: We identified patients
with an HCV diagnosis and either laboratory confirmation or a second diagnosis
within a year. We excluded those with no encounters at least 6 months before the
first diagnosis to ensure treatment naiveté. Cox Proportional Hazards regression
models were developed with contraindications as time-varying exposures to as-
sess their influence on treatment likelihood. RESULTS: Of 318,814 previously un-
treated veterans diagnosed from 2004-2009, 101,444 (31.8%) met all criteria. Mean
(SD) age was 58.6 (8.2) years and 96.7% were male. Race was known in 51.9%; of
which most were white (49.9%) or black (40.4%). At diagnosis, most patients had
unknown genotype (56.4%) or genotype 1 (35.3%). Contraindications were present
at diagnosis in 17.2% of patients and 30.1% developed contraindications during
follow-up. Predictive models revealed that several contraindications were signifi-
cantly and independently associated with a decreased likelihood of treatment in-
cluding kidney transplant (hazards ratio [HR]0.29), thrombocytopenia (HR0.38),
acute myocardial infarction (HR0.43), iron-deficiency anemia (HR0.46), acute
coronary syndromes (HR0.62), bipolar disorder (HR0.63), hepatic decompensa-
tion (HR0.70), and retinopathy (HR0.74). Patients with a liver transplant were
much more likely to receive treatment (HR3.51). Contraindications that had no
influence on the likelihood of treatment were intractable epilepsy, pregnancy, ma-
jor depression, and hemoglobinopathies. Neutropenia, auto-immune hepatitis,
and other organ transplant had too few events and so were dropped from the
models. CONCLUSIONS: This study provides evidence that clinicians make real-
world treatment decisions for HCV based on some contraindications but not all.
Future work should examine the occurrence of adverse events or treatment failure
in contraindicated patients and explore ways to improve clinician awareness of
contraindications when making treatment decisions.
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Rotavirus vaccination in infants has been reimbursed in Belgium since November
2006 and vaccine coverage is about 85%.OBJECTIVES:To assess and to compare the
impact of mass rotavirus vaccination on the rotavirus related hospitalisations in
children5 y old pre-vaccination and up to 4 years post-introduction of the vaccine
in 9 paediatric wards in Belgium. METHODS: Stool samples for rotavirus detection
were collected from all 5y old hospitalised children. The absolute number of
rotavirus positive tests pre-vaccine launch (01/06/2004-31/05/2006) were compared
with data at launch (01/06/2006-31/05/2007), and post-launch (01/06/2007-31/05/
2011). Data are presented as a % reduction (95% CI) per year post-vaccination con-
sidering the annual average pre-vaccination period as a reference. RESULTS: The
number of rotavirus-positive stool tests in children aged 5 years decreased from
an average of 881 pre-vaccination to 600, a 32% reduction (95% CI: 29%-35%) during
the launch period, to 368 (58%, 95% CI: 55%61%) in the 1st year post-launch, to
202 (77%, 95% CI: 74%80%) in the 2nd year, 180 (80%, 95% CI: 77%82%) in the
3rd year, and to 201 (77%, 95% CI: 74%80%) in the 4th year. In addition an overall
decline (38%, 95% CI: 36%41%) in all-cause acute-gastroenteritis (AGE) related
hospital admissions is observed from 1,757 per year pre-vaccination to 1,082 per
year 4th year post-launch. The number of bed days due to AGE has fallen from 8974
pre-vaccination to 5362 (40%, 95% CI: 39%41%) post-vaccination. A reduction
from 6340 to 4894 (27%, 95% CI: 26%28%) is also seen amongst the non-rotavirus
positive cases. CONCLUSIONS: Significant declines in number of rotavirus and
all-cause AGE related hospitalisations are seen in young children after 4 years of
mass rotavirus vaccination in Belgium. A steady state may be reached after 3 years
as no further decrease in the number of rotavirus related hospitalisations is ob-
served.
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OBJECTIVES: Perform pharmacoepidemical analysis on actual practice when using
antibacterial therapy among adults with acute bronchitis. METHODS: We have
analyzed 572 cases of acute bronchitis among patients receiving clinical treatment
in four hospitals located in Moscow, Nizhniy Novgorod, St. Petersburg and Kazan.
An individual registration folder featuring patient’s demographic data, accompa-
nying diseases, use of antimicrobial treatment, dose regimes and methods and
length of treatment was filed for pharmacoepidemical research. The average age of
patients was 39.85,7 years with 74% of men and 26% of women. RESULTS: Anti-
biotics were used in 85.7% of all cases. In Nizhniy Novgorod antimicrobial pills were
given to 85% of patients while the number of such patients in Moscow and St.
Petersburg amounted to 88.5% and 81.5% respectively. In Kazan all the patients
received antimicrobial drugs. The most frequent drugs were macrolides (45.8%),
inhibitor-protected penicillin (43.7%) and fluoroquinolines (ciprofloxacin) (4.9%).
The less frequent ones were doxycycline (1.6%) and amoxicillin (1.8%) and ampi-
cillin (2.2%). The most frequent macrolid was azitromicyn (33.7%) as well as clar-
ythromycin (8.6%) and erythromycin (3.5%). CONCLUSIONS: As a result the actual
practice of clinical treatment of acute bronchitis among adults majorly requres the
use of antibacterial wide spectrum drugs (85.7%). The frequency of such therapy
was high in all hospitals regardless of their locations. The use of antibiotics when
treating virus etiology is obviously wrong and leads to the increase of non-desired
consequences, higher cost of treatment and might be accompanied by the growing
number of antibiotic resistant microorganisms. The above-mentioned data re-
quires to create and practice methods aimed at the reduction of antimicrobial
drug-taking for patients with acute bronchitis in clinical treatments.
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OBJECTIVES: Streptococcus pneumoniae (SP) pneumonia represents substantial
morbidity and mortality worldwide. A retrospective study was conducted to de-
scribe the incidence, serotype distribution, and in-hospital mortality associated
with reportable invasive SP pneumonia in all age groups in Norway from
2007–2009. METHODS: Patients with laboratory-confirmed invasive SP pneumonia
were identified from the Norwegian Surveillance System for Communicable Dis-
eases (MSIS) database from January 2007–December 2009. Population data were
obtained from Statistics Norway. Incidence was reported annually as new cases per
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